Picture loading failed.

Pre-made Erfonrilimab benchmark antibody (Bispecific Single Domains (VH-VH'-CH), anti-CD274/PD-L1;CTLA4/CTLA-4 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-194-1mg 1mg Inquiry
GMP-Bios-ab-194-10mg 10mg Inquiry
GMP-Bios-ab-194-100mg 100mg Inquiry
GMP-Bios-ab-194-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-made Erfonrilimab biosimilar, Bispecific Single Domains (VH-VH'-CH), Anti-CD274/PD-L1;CTLA4/CTLA-4 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name Erfonrilimab
TargetPD-L1;CTLA-4
FormatBispecific Single Domains (VH-VH'-CH)
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCna;na
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;6rqm:B
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
CompaniesAlphamab
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Triple-negative breast cancer;Esophageal carcinoma
Conditions Discontinuedna
Development Techna